Nitroglycerin Sustained Release Tablet. Formulation Design and Evaluation

Bhadra, Subrata

ISBN 10: 3656476985 / ISBN 13: 9783656476986

Edité par Grin Verlag, 2013

A propos de cet article

N° de réf. du vendeur I-9783656476986

Détails bibliographiques

Titre : Nitroglycerin Sustained Release Tablet. ...

Éditeur : Grin Verlag

Date d'édition : 2013

Reliure : Couverture souple

Etat : New

A propos de ce titre

Synopsis :

Master's Thesis from the year 2010 in the subject Medicine - Pharmacology, Pharmacy, University of Dhaka (M. Pharm, in Pharmaceutical Technology), language: English, abstract: The aim of the present studies was to develop and characterize 2.6 mg sustained release matrix tablets of Nitroglycerin. Tablets were prepared by direct compression method. Methocel K15M CR and Methocel K100LV CR polymers were used as rate retarding agents in nine formulations (F-1 to F-9). The granules were evaluated for angle of repose, loose bulk density, tapped bulk density, Carr's index, Hausner ratio, moisture content, total porosity and assay. The tablets were subjected to diameter, thickness, assay, uniformity of content, assay after 1Month at 40°C+75%RH, hardness, friability, and in vitro dissolution studies. The granules showed satisfactory flow properties, compressibility, and drug content. All the tablet formulations showed acceptable pharmacotechnical properties and complied with pharmacopoeial specifications for tested parameters. The in vitro dissolution study was carried out for 8 hour using USP-2009 Apparatus-I (Rotating basket method) in distilled water as the dissolution medium. The release mechanisms were explored and explained by Zero order, First order, Higuchi, Korsmeyer-Peppas and Hixson-Crowell equations. Nine formulations were prepared by using three variable ratio of two polymers; Methocel K15M CR (25%, 20% and 15%) and Methocel K100LV CR (15%, 10% and 5%) where all the formulations (F-1 to F-9) contained 0.5% colloidal silicon dioxide and 1% magnesium stearate. Among these nine formulations, six formulations; F-2 (Methocel K15M CR: Methocel K100LV CR = 25%: 10%), F-3 (Methocel K15M CR: Methocel K100LV CR = 25%: 5%), F-4 (Methocel K15M CR: Methocel K100LV CR = 20%: 15%) F-5 (Methocel K15M CR: Methocel K100LV CR = 20%: 10%), F-6 (Methocel K15M CR: Methocel K100LV CR = 20%: 5%) and F-7 (Methocel K15M CR: Methocel K100LV CR = 15%: 15%) met the official specifi